CD14 and triple-negative breast carcinoma: Furthermore, a phase II trial in patients with metastatic, triple-negative breast cancer showed that cabozantinib continuously increased the number of circulating CD3 + T-lymphocytes while continuously decreasing CD14 + monocytes, suggesting that cabozantinib treatment led to bolstered antitumor immunity [44].